ANNEXON, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.65 USD | +1.53% |
|
-8.28% | +2.42% |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to Annexon's GBS Program Up...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications. It has developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery.
Sector
Pharmaceuticals
Calendar
2024-08-04
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.65
USD
Average target price
15.67
USD
Spread / Average Target
+236.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.42% | 483M | |
| +1.87% | 94.22B | |
| -4.08% | 37.76B | |
| -13.26% | 32.5B | |
| +73.38% | 27.75B | |
| -11.58% | 16.13B | |
| -1.66% | 14.19B | |
| -11.67% | 11.42B | |
| +190.36% | 11.06B | |
| -52.61% | 9.09B |
- Stock Market
- Equities
- ANNX Stock
- News Annexon, Inc.
- Transcript : Annexon, Inc. - Special Call
